Biocontrol
This company is in the business of creating and marketing brain supplements.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
Biocontrol Limited, founded in 1997, operates in the biotechnology sector, specializing in the development of biological agents to combat bacterial infections. The company's core technology revolves around bacteriophages, which are viruses that infect and destroy specific bacteria. This approach offers a targeted method for addressing bacterial threats, particularly *Pseudomonas aeruginosa*, a common cause of ear infections, hospital-acquired infections, and complications in cystic fibrosis patients.
Originally based in the United Kingdom, the clinical-stage company focused its research and development on creating anti-infective drugs derived from these naturally occurring microorganisms. The lead product candidate successfully completed a Phase 2 clinical trial for treating *Pseudomonas aeruginosa* infections in cases of otitis (ear infections). Additionally, Biocontrol was actively developing treatments for lung infections affecting individuals with cystic fibrosis. The company's business model centered on the research, development, and eventual commercialization of these specialized therapeutic agents. Revenue generation was anticipated through the successful launch and sale of its bacteriophage-based products to healthcare providers and pharmaceutical partners.
In a significant strategic move, Biocontrol was acquired by AmpliPhi Biosciences in January 2011. This merger was designed to leverage Biocontrol's scientific programs with Targeted Genetics' (AmpliPhi's former name) expertise and assets in gene therapy. Prior to the acquisition, Biocontrol had secured $1.01 million in funding from investors, including E-Synergy and The Capital Fund. The acquisition involved Targeted Genetics issuing over 22.5 million shares of its common stock to Biocontrol's former shareholders. Following the merger, Biocontrol's key leadership, including CEO Edward C. Cappabianca and Chief Scientific Officer Dr. David Harper, transitioned into executive roles at the newly combined entity to continue the development of bacteriophage programs. Keywords: bacteriophage, anti-infective, biotechnology, Pseudomonas aeruginosa, bacterial infections, drug development, cystic fibrosis, clinical trials, life sciences, gene therapy